Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
By Stephanie G. Downey, J. Klapper, F. Smith, Jie Yang, R. Sherry, R. Royal, U. Kammula, M. Hughes, T. Allen, Catherine L. Levy and 5 more. Clinical Cancer Research, 2007
631 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/eeab4ec43aa2a95a1e11c1cd581219bfdfb05925
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Oncology
Citations in the corpus
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015, background): “It is possible that irAEsmaybe associatedwithdurable response and clinical benefit and that association has previously been studied with anti–CTLA-4 therapy (19), although contradictory reports exist (20).”
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013, background): “It should be noted, however, that these events were more common in patients with the best tumor response to treatment (Attia et al., 2005; Downey et al., 2007).”
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (2015, background): “Downey [24] Multicenter, single arm, phase II Melanoma 139 Ipilimumab 9 n/a”
- The blockade of immune checkpoints in cancer immunotherapy (2012, background): “Interestingly, although there is evidence that clinical responses might be associated with immune-related adverse events, this correlation is modes”
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, neutral): “497 Present 4 (31) 4 (100) 0 (0) 4 (100) 0 (0) CD4:CD8 (n 1⁄4 29) CD4 CD8 13 (45) 10 (77) 3 (23) 0.”
- Management of toxicities of immune checkpoint inhibitors. (2016, background): “[52, 79, 80] A retrospective evaluation of 139 patients of ipilimumab given at varying doses also found irAEs to be predictive of response and survival and the highest response rate was seen in those who had grade 3 and 4 toxicity.[81] In patients treated with ipilimumab at 10mg/kg, use of steroids ”